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Background: A biomarker that is of great interest in relation to adverse cardiovascular 
events is soluble ST2 (sST2), a member of the interleukin family. Considering that meta-
bolic syndrome (MetS) is accompanied by a proinflammatory state, we aimed to assess 
the relationship between sST2 and left ventricular (LV) structure and function in patients 
with MetS. 
Methods: A multicentric, cross-sectional study was conducted on180 MetS subjects with 
normal LV ejection fraction as determined by echocardiography. LV hypertrophy (LVH) was 
defined as an LV mass index greater than the gender-specific upper limit of normal as de-
termined by echocardiography. LV diastolic dysfunction (DD) was assessed by pulse-wave 
and tissue Doppler imaging. sST2 was measured by using a quantitative monoclonal 
ELISA assay.
Results: LV mass index (β=0.337, P <0 .001, linear regression) was independently asso-
ciated with sST2 concentrations. Increased sST2 was associated with an increased likeli-
hood of LVH [Exp (B)=2.20, P =0.048, logistic regression] and increased systolic blood 
pressure [Exp (B)=1.02, P =0.05, logistic regression]. Comparing mean sST2 concentra-
tions (adjusted for age, body mass index, gender) between different LV remodeling pat-
terns, we found the greatest sST2 level in the group with concentric hypertrophy. There 
were no differences in sST2 concentration between groups with and without LV DD.
Conclusions: Increased sST2 concentration in patients with MetS was associated with a 
greater likelihood of exhibiting LVH. Our results suggest that inflammation could be one of 
the principal triggering mechanisms for LV remodeling in MetS.
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INTRODUCTION
Metabolic syndrome (MetS) is a group of the most common 
cardiovascular disease (CVD) risk factors: raised fasting plasma 
glucose, abdominal obesity, dyslipidemia and hypertension, as 
well as genetics, aging, and a proinflammatory state, which 
have been shown to increase cardiovascular (CV) morbidity and 
mortality [1, 2].The association between MetS and adverse CV 
outcomes is independent of diabetes mellitus (DM) and arterial 
hypertension [3]. In addition, MetS has been associated with 
changes in cardiac structure and function, including left ven-
tricular (LV) hypertrophy and subclinical LV systolic and/or dia-
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stolic dysfunction [4]. Alterations in LV structure and function of 
patients with MetS could be an important link to CV morbidity 
and mortality [3]. The prevalence of LV hypertrophy (LVH) and 
LV dysfunction significantly increased with the presence of an 
increasing number of risk factors [5]. One of the factors that 
certainly contributes to MetS is a proinflammatory state. A bio-
marker that is currently of interest in relation to this is soluble 
ST2 (sST2), a member of the interleukin (IL)1 receptor host de-
fense and inflammation family [6, 7].
In patients with increased sST2 concentrations, protective 
functions of IL-33 may be inhibited, leading to maladaptive car-
diac remodeling with fibrosis, hypertrophy, and loss of function 
[8]. Recently, sST2 has been reported to be increased in pa-
tients with heart failure, myocardial infarction, hypertension, se-
vere obesity, and diabetes [9-14]. sST2 emerged as a prognos-
tic biomarker for both nonfatal cardiac events and mortality in 
high-risk patients [15]. With regards to LV remodeling in MetS, 
there is no available data on sST2 concentrations and their pos-
sible influence on LV structure and function.  
The aim of the present study was to determine the link be-
tween proinflammatory factors, namely sST2, and LV remodel-
ing in patients with MetS, as a potentially useful tool in early as-
sessment of MetS patients. 
METHODS
A multicentric, cross-sectional study was conducted at univer-
sity hospital centers in Italy, Serbia, and Spain, from April 2013 
to October 2014.
The study included 180 consecutive subjects who were re-
ferred from outpatient clinics where they were screened for 
MetS. The study was conducted in compliance with the Decla-
ration of Helsinki, and the Ethics Committees of all the institu-
tions where research was conducted approved the research 
protocol. Informed consent was obtained from all subjects.
Demographic and clinical parameters of the study population 
are presented in Table 1.
The study group included almost equal proportions of men 
and women, aged less than 65 yr, exhibiting central obesity and 
the other MetS criteria. About 94% of the subjects had hyper-
tension, with an average therapy duration of seven years. Diabe-
tes was present in 25% of subjects, with an average duration of 
less than two years. 
All participants underwent physical, laboratory, and echocar-
diographic examinations. 
Arterial blood pressure (BP) was obtained by taking the aver-
age value from at least two BP measurements in the sitting posi-
tion within a 1-2 min interval [16]. Anthropometric measure-
Table 1. Demographic characteristics and clinical parameters of the study population
Variables n=180 Variables n=180
Age (yr) 52.63±8.95 CCB   72 (40%)
Heart rate (1/min) 72.07±12.22 Diuretics 73 (40.6%)
Gender (males) 93 (51.7%) Lipid lowering therapy    72 (40%)
SBP (mm Hg) 139.55±18.48 Plasma glucose (mmol/L) 6.03±1.67
DBP (mm Hg)   83.96±12.31 HbA1c (mmol/L) 6.12±0.95
Waist circumference (cm) 102.85±10.10 Cholesterol (mmol/L) 5.46±1.23
BMI (kg/m2) 30.58±4.77 HDL cholesterol (mmol/L) 1.16±0.40
BSA (m2) 2.01±0.21 LDL cholesterol (mmol/L) 3.44±1.10
DM 45 (25%) Triglycerides (mmol/L) 2.13±1.49
DM duration (yr) 1.89±4.44 Serum creatinine (μmol/L) 72.62±18.22
HTA 169 (93.9%) eGFR (mL/min) 123.48±37.87
HTA duration (yr) 7.01±4.83 Potassium (mmol/L) 4.41±0.39
ACEi 105 (58.3%) Sodium (mmol/L) 139.96±3.18
ARB  43 (23.9%) Hb (g/L) 142.78±15.38
BB  79 (43.9%) ST2 (ng/mL) 27.35±15.74
Data are presented as mean±SD or n (%).
Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index; BSA, body surface area; DM, diabetes mellitus; HTA, hy-
pertension; ACEi, angiotensin-converting-enzyme inhibitor; ARB, angiotensin II receptor blocker; BB, β blocker; CCB, calcium channel blocker; HDL, high 
density lipoprotein; LDL, low density lipoprotein; eGFR, estimated glomerular filtration ratio.
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ments (height, weight, waist circumference) were taken for all 
subjects. Body surface area (BSA) and body mass index (BMI) 
were calculated. Regarding MetS and laboratory analyses, we 
determined the levels of fasting glucose, total cholesterol, high 
density lipoprotein (HDL) cholesterol, and triglycerides. Addi-
tional laboratory tests included analyzing hemoglobin, sodium, 
and potassium levels, as well as measures of renal function 
(creatinine and glomerular filtration rate). All study participants 
underwent biomarker testing for N-terminal pro-hormone B-
type natriuretic peptide (NT-proBNP) and sST2. Samples were 
collected from each patient and stored at -25°C. They were 
transported via airplane on dry ice without any delay during 
transportation, and processed at a local laboratory in Rome 
upon arrival. Levels of sST2 were stable during the transporta-
tion process. 
MetS was diagnosed according to the new International Dia-
betes Federation (IDF) definition as the presence of central obe-
sity and at least two of the following factors: triglycerides ≥1.7 
mmol/L (or specific treatment for this lipid abnormality), HDL 
cholesterol <1.03 mmol/L in males and <1.29 mmol/L in fe-
males (or specific treatment for this lipid abnormality), systolic 
BP ≥130 or diastolic BP ≥85 mm Hg (or treatment of previously 
diagnosed hypertension), and fasting plasma glucose ≥5.6 
mmol/L. Central obesity was assumed if BMI was >30 kg/m2, or 
waist circumference was ≥102 cm in males and ≥88 cm in fe-
males [17, 18].
Study inclusion criteria consisted of MetS, age <65 yr, normal 
LV ejection fraction (EF) (≥50%), and normal concentration of 
NT-proBNP. Exclusion criteria were: symptoms or signs of heart 
failure, cardiac arrhythmia with hemodynamic instability, docu-
mented coronary artery disease, previous cerebrovascular 
events, congenital or valvular heart disease, liver cirrhosis, kid-
ney failure, anemia, malignant disease, and alcoholism. 
The duration of hypertension was defined by the length of an-
tihypertensive drug usage. The duration of diabetes was defined 
by the length of the specific therapy regimen. 
1. Laboratory assays
All patients underwent sST2 testing at admission. Blood sam-
ples from all centers were shipped to the central laboratory in 
Rome. Testing was performed by using Presage ST2 (Critical Di-
agnostics, San Diego, CA, USA), a quantitative monoclonal 
ELISA assay in a 96-well plate (ELISA PLATE READER DAS 
S.R.L; model A3 and C, Rome, Italy). In each well, we added 
100 µL of blood serum. Normal sST2 values for patients in good 
health are divided by sex as follows: 23.6±2.3 ng/mL for men 
and 16.2±1.2 ng/mL for women. 
2. Echocardiographic study
Echocardiographic images were obtained by using a 2.5-MHz 
transducer with harmonic capability, in all centers, using a Vivid 
7 (General Electric, Boston, MA, USA) echo machine. A com-
plete two-dimensional echocardiographic (2DE) study was per-
formed in the left lateral decubitus position, according to recom-
mendations from the American Society of Echocardiography 
(ASE) [19]. Reported values of all echocardiographic parame-
ters represent the average value of three consecutive cardiac 
cycles. 
Relative wall thickness (RWT) was calculated as (2×LV poste-
rior wall thickness)/LV internal end-diastolic diameter. LV end-
systolic and end-diastolic volumes and EF were calculated by 
using the biplane method. Left atrial (LA) volume was calculated 
by using the LA areas and lengths measured from both the api-
cal four- and two-chamber views. LV and LA volumes were in-
dexed by BSA. For calculating LV mass, we used a formula pro-
posed by Devereux and colleagues (ASE): LV mass=0.8 (1.04 
([LVIDD+PWTD+IVSTD]3-[LVIDD]3))+0, 6 g, where IVSTD is the 
diastolic interventricular septum thickness, PWTD is the diastolic 
posterior wall thickness, and LVIDD is the LV internal diastolic di-
ameter [19]. LV mass was indexed by BSA (LV mass index 
[LVMI]). LV hypertrophy was defined by LVMI ≥116 and ≥96 g/m2 
in men and women, respectively. Remodeling patterns of LV 
were categorized regarding RWT and LVMI as: normal LV geom-
etry, normal LVMI and RWT ≤0.42; concentric remodeling, nor-
mal LVMI with increased RWT >0.42; concentric hypertrophy, 
increased LVMI and increased RWT >0.42; eccentric remodel-
ing, increased LVMI and RWT ≤0.42 [19]. Transmitral pulsed 
Doppler inflow included measurements of early diastolic mitral 
flow velocity (E), deceleration time (DT), late diastolic mitral flow 
velocity (A), and E/A ratio [20]. Tissue Doppler imaging was used 
in the apical 4-chamber view with a sample volume placed at 
the septal and lateral segment of the mitral annulus during early 
and late diastole (e’ and a’). The average of the peak early dia-
stolic relaxation velocity (e’) was calculated, as well as the E/e’ 
average ratio [20]. Doppler timed LV interval (in milliseconds), 
the isovolumic relaxation time (IVRT), was measured with contin-
uous Doppler by aiming the Doppler beam at an intermediate 
position between inflow and outflow to record both velocities. 
IVRT was measured as the interval between the end of ejection 
and the onset of mitral inflow [20]. Left ventricular internal diam-
eter-diastole LVIDD was assessed by Doppler parameters (E/A 
ratio, DT, e’ lateral, e’ septal), following the recommendations of 
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the European and the American Society of Echocardiography 
[21, 22].
3. Statistical analyses
Continuous variables are presented as mean±SD. Normality of 
data sets was assessed by the Kolmogorov-Smirnov test. When 
data did not follow normality assumptions and non-normality 
was due to a valid reason (real observed data points of sST2), 
data were transformed to obtain normality by applying a loga-
rithmic transformation (LogsST2). An independent samples t-
test was used to compare means from two groups. Differences 
in proportions were compared by using a chi-square test. Pear-
son’s correlation coefficients were used for determining the cor-
relation between 2D LV parameters, sST2, and the other param-
eters. P values <0.05 (two-sided) were considered statistically 
significant. The variables that showed P values ≤ 0.10 were in-
cluded into the stepwise linear regression analysis. A logistic re-
gression was performed to determine the effects of different pa-
rameters on the likelihood that participants had LVH and LVDD. 
A general linear model and the analysis of equal variance with 
Bonferroni post hoc analysis were used to detect differences 
between four groups of LV remodeling patterns. The accuracy of 
the sST2 test for distinguishing between patients with and with-
out LVH was assessed from ROC curve analysis. 
RESULTS
sST2 concentrations were increased above normal values in the 
study group as a whole. In addition to the mean value of sST2 
listed in Table 1, the median concentration of sST2 for the 
group was 23 ng/mL.
Regarding MetS parameters as inclusion criteria, all partici-
pants, males and females, had similar systolic BP (SBP), dia-
stolic BP (DBP), and plasma glucose levels. Males were 
younger, with higher BMI and waist circumference than fe-
males, and had higher levels of serum triglycerides on average. 
Females had higher levels of HDL (Table 2).
Results of 2D echocardiographic examinations of LV structure 
and function in subjects with MetS are shown in Table 3. Mean 
values of LA dimensions, LV volumes, and EFs were normal. 
There was an increased diastolic thickness of the septum and 
posterior wall, as well as an increased relative wall thickness. 
Overall, parameters of LV diastolic function (E/A, e’/a’ average, E/ e’ 
average) were impaired in study participants. 
Correlation analysis demonstrated that HDL (r=-0.188, P = 
0.022), IVSTD (r =0.185, P =0.023), PWTD (r =0.225, P = 
0.006), LV mass (r=0.286, P =0.000), LVMI (r=0.304, P = 
0.000), DT (r=-0.181, P =0.029), and IVRT (r=-0.228, P = 
0.008) were significantly related to sST2, but correlation coeffi-
cient was relatively weak. 
When these parameters were added in the linear regression 
model, stepwise method, only LVMI (β=0.337, P =0.000), IVRT 
(β=-0.256, P =0.002), and HDL (β=- 0.199, P = 0.013) were 
independently associated with sST2 concentrations, which is 
shown graphically in Fig.1.
LVH was found in 48 (26.7%) subjects. LVMI was normal in 
132 (73.3%) subjects. sST2 was significantly higher in patients 
with LVH than in patients without LVH (32.18±16.88 ng/mL vs 
25.94±15.19 ng/mL, P =0.042).
A logistic regression was performed to determine the effects 
of age, BMI, gender, SBP, DBP, therapy, and sST2 concentra-
tion on the likelihood of participants having LVH. The logistic re-
gression model was statistically significant (χ2 =9.65, P =0.008). 
The model correctly classified 89% of cases. Increased sST-
2concentration was associated with an increased likelihood of 
exhibiting LVH [Exp (B)=2.20, P =0.048] as well as increased 
SBP [Exp (B)=1.02, P =0.05]. Males with MetS were 2.51 
times more likely to exhibit LVH than females (P =0.001).
Table 2. Metabolic syndrome parameters and soluble ST2 (sST2) 
concentration in study participants
Variable Gender Mean P
Age (yr) Male 50.47±9.23 0.001
Female   55.10±7.93
SBP (mm Hg) Male 139.38±17.37 0.902
Female 139.73±19.69
DBP (mm Hg) Male 85.26±13.03 0.126
Female 82.59±11.41
BMI (kg/m2) Male 31.82±4.49 0.000
Female   29.25±4.72
Waist circumference (cm) Male 107.06±8.21 0.001
Female   99.72±10.25
Plasma glucose (mmol/L) Male   6.09±1.76 0.642
Female   5.97±1.56
HDL cholesterol (mmol/L) Male   1.02±0.29 0.000
Female   1.31±0.45
Triglycerides (mmol/L) Male   2.38±1.78 0.016
Female   1.85±1.04
sST2 (ng/mL) Male  26.24±13.88 0.336
Female 28.73±17.81
Data are presented as mean±SD.
Abbreviations: See Table 1. 
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We performed ROC analysis for sST2, and the classification 
variable was LVH. ROC analysis showed that testing for sST2 
has the ability to distinguish between the two groups; the area 
under the ROC was 0.62, P =0.02 (95% confidence interval 
[CI]: 0.557, 0.724). This relatively low area under the ROC in 
our study indicates that non-invasive risk scores regarding LVH 
and sST2 concentrations in patients with MeS needs further re-
finement and testing (Fig. 2).
Youden index was criteria used to find the optimal sST2 
threshold point (>30.94) from the ROC curve for sST2 and in-
creased LVMI, with CI of 14.81-49.76, sensitivity of 44.12%, 
and specificity of 77.78%.
Comparing mean concentrations of sST2 between different 
remodeling patterns of LV, using GLM, we found the highest 
sST2 concentration in the group of subjects with concentric hy-
pertrophy (Table 4). 
Among study participants, 101 (56.1%) subjects had impaired 
Table 3. Two-dimensional echocardiographic (2DE) parameters of 
left ventricular structure and function in the study population
2DE variables Value
Left atrial diameter (mm) 39.27±4.61
Interventricular septum thickness (mm) 10.40±1.52
Posterior wall thickness (mm) 10.31±1.36
LV end-diastolic diameter (mm) 48.55±5.70
LV end-systolic diameter (mm) 32.08±5.42
Relative wall thickness (cm) 0.43±0.08
LV mass (g) 182.02±44.60
LV mass index (g/m2) 90.63±20.90
LV end-diastolic volume (mL) 104.53±28.13
LV EDVi (mL/m2) 52.42±13.91
LV end-systolic volume (mL) 42.37±15.17
ESVi (mL/m2) 21.15±7.22
EF biplane (%) 60.56±6.61
Left atrial volume (mL) 45.82±22.88
Left atrial volume/BSA (mL/m2) 22.77±10.93
E (m/s) 0.70±0.17
A (m/s) 0.74±0.18
E/A 0.99±0.33
DT (ms) 214.49±48.99
IVRT (ms) 82.45±23.75
e´_septal (m/s) 0.07±0.02
e´_lateral (m/s) 0.10±0.07
e´average (m/s) 0.08±0.04
a´_septal (m/s) 0.10±0.02
a´_lateral (m/s) 0.11±0.03
a´average (m/s) 0.10±0.02
E/e´average 8.37±2.84
e´/a´average 0.85±0.39
Data are presented as mean±SD.
Abbreviations: See Table 1; LV, left ventricular; EDVi, end-diastolic volume 
indexed by BSA; ESVi, end-systolic volume indexed by BSA; A, late diastolic 
mitral flow (pulse Doppler); E, early diastolic mitral flow (pulse Doppler); 
IVRT, isovolumic relaxation time; DT, deceleration time; e´, peak early dia-
stolic relaxation velocity of the septal and lateral mitral annulus (tissue Dop-
pler); a´, peak late diastolic relaxation velocity of the septal and lateral mitral 
annulus (tissue Doppler).
Fig. 1. Partial regression plot: Relation between soluble ST2 (sST2) 
and two-dimensional echocardiographic left ventricular (LV) mass 
index.   
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LV DD. Regardless of sST2 correlating with IVRT as the parame-
ter of LV DD, there were no differences in the mean sST2 serum 
concentration between groups with and without LV DD (29.77 
ng/mL±15.87 ng/mL vs 25.85 ng/mL±15.16 ng/mL, P =0.303). 
LV DD was linked to SBP [Exp (B)=1.19, P =0.05], age [Exp 
(B)=1.19, P =0.001], and LVMI [Exp (B)=1.044, P =0.045].
DISCUSSION  
The principal finding of the present study was that sST2concen-
tration increased in patients with MetS, and was significantly re-
lated to LV remodeling. The serum concentration of sST2 in 
MetS patients was not linked to age, gender, or history of hyper-
tension or diabetes. In addition, we did not find a significant 
correlation with most of MetS factors: BMI, waist circumference, 
BP, plasma glucose and triglycerides. 
In The Dallas Heart Study (DHS), sST2 concentrations were 
not significantly associated with most traditional CV risk factors 
or subclinical CV disease [15]. In the Framingham heart study 
(FHS), sST2 concentrations differed between men and women, 
increased with age, and were associated with diabetes and hy-
pertension [11]. The DHS and the FHS were large, population-
based studies. In the study by Ojji et al [12], BP in hypertension 
patients did not differ significantly between four groups of LV re-
modeling patterns. Therefore, BP did not influence sST2 con-
centration, which was higher in the concentric hypertrophy 
group. The results of the study conducted by Fousteris et al [14] 
indicate that type 2 diabetes is associated with higher sST2 con-
centrations, which are positively correlated with CRP levels and 
the extent of glycemic control. In this study, there was a control 
group with normal glucoregulation, while the MetS study did not 
include controls. Our results are related to a specific group of 
patients with MetS, which, by definition, already includes risk 
factors and their interactions. This could explain the lack of cor-
relation between sST2 and risk factors. sST2 was recently 
shown to be expressed in adipose tissue macrophages [13, 23]. 
Waist circumference and BMI of our patients were in accor-
dance with MetS criteria for central obesity.
We demonstrated that parameters of LV structure and sub-
clinical DDwere considerably related to sST2. Among the dys-
function parameters, only LVMI and IVRT were independently 
associated with sST2 concentration. Increased sST2concentra-
tion was associated with an increased likelihood of exhibiting 
LVH, as well as increased SBP. In addition, LVH was gender-re-
lated: males with MetS were 2.5 times more likely to show LVH 
than females. Elevated BP and hormones are well known pre-
dictors of LVH. Our results indicate that the proinflammatory 
state as determined by elevated sST2 is a more powerful LVH 
contributing factor than SBP in MetS.  
The mechanism of sST2 action in the heart is not fully under-
stood. ST2 is a member of the IL-1 receptor family. The gene 
encoding ST2 is clearly upregulated in cardiomyocytes and fi-
broblasts during mechanical stretch [7, 9]. This gene encodes a 
protein that consists of a functionally active (via binding to IL-
33) transmembrane ST2 receptor form (ST2L) and a soluble re-
ceptor form (sST2) that can be detected in serum [8]. Cardio-
myocytes and cardiac fibroblasts show a concordant increase in 
release of both ST2L and sST2 under biomechanical strain [8]. 
This release is an important step in the overall mechanism of in-
ducing cardiac remodeling due to volume and/or pressure over-
load [24]. The pitfall of this action lies in the fact that presence 
of large amounts of sST2 may be a “decoy” receptor, acting as 
a sort of “off switch” for ST2/IL-33 signaling [8]. In the context 
of CV damage, ST2L/IL-33 reduces cardiac remodeling, fibrosis, 
and hypertrophy. Possibly, IL-33 can exert an antihypertrophic 
effect by preventing the actions of angiotensin II or phenyleph-
rine on myocardium [24]. It was recently shown that in CVD 
models, IL-33 reduces atherosclerotic plaque formation or car-
diac hypertrophy secondary to pressure overload [25]. These 
protective effects of ST2L/IL-33 on cardiac remodeling could be 
blocked by the presence of large amounts of sST2 competing 
for IL-33. At the same time, released IL-33 is recognized by dif-
ferent immune cells that produce proinflammatory mediators, 
and can induce endothelial activation. Both macrovascular (aor-
tic and coronary artery) and heart microvascular endothelial 
cells are sources of sST2 protein [26].
Table 4. Serum soluble ST2 (sST2) level differences between patterns of left ventricular remodeling (fixed factor), adjusted for age, body 
mass index (covariates), and gender (random factor)
Variable
Normal LV geometry 
(n=64)
 Concentric LV remodeling 
(n=68)
Concentric LV hypertrophy 
(n=20)
Eccentric LV remodeling 
(n=28)
sST2 (ng/mL) 23.94±2.26* 27.53±1.92† 41.16±4.15 27.48±3.69
Data are presented as mean±SD; Adjustment for multiple comparisons: Bonferroni; mean difference is significant at the 0.05 level.
*normal LV remodeling vs concentric LV hypertrophy (P =0.003); †concentric LV remodeling vs concentric LV hypertrophy (P =0.019).
Abbreviation: LV, left ventricular. 
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This situation with modulated proinflammatory response 
could easily be translated to other similar scenarios of increased 
volume and/or pressure overload and impaired overall homeo-
stasis, such as MetS. 
Our results confirmed that increased sST2 concentrations in 
MetS were associated with LV remodeling. sST2 concentrations 
were significantly elevated in MetS patients with LVH, and the 
highest sST2 concentrations were found in the group of MetS 
subjects with concentric hypertrophy, which agrees with the re-
sults of the study by Ojji et al [12]. This author, in the group of 
hypertensive patients, showed that sST2 is a useful biomarker 
for distinguishing hypertensive LVH from hypertension without 
LVH [12]. We also showed that increased sST2 concentrations 
could be helpful for making a distinction between MetS patients 
with and without LVH, but the area under the ROC was 0.62, 
implying relatively poor accuracy, and the optimal cut-off value 
of sST2 had low sensitivity.  
Regarding LV function, parameters of diastolic function were 
generally impaired in patients with MetS. Even though sST2 
concentration correlated with IVRT, there was no difference in 
sST2 concentration between groups with and without LVDD. A 
greater likelihood of having impaired LV diastolic function was 
seen in MetS patients who were older, had increased SBP, and 
had increased LVMI. This result is in accordance with the find-
ings of Wang et al [27] in a group of hypertensive patients. Au-
thors reported a poor correlation between sST2 concentration 
and diastolic parameters in hypertensive patients with stable 
heart failure and normal LV EF.
A limitation of the present study is that it does not have an in-
herent temporal dimension, because it was a cross-sectional 
study. We recognize that the lack of follow-up data could be a 
limitation of this study regarding the prognostic significance of 
our results. 
To our knowledge, the present study is the first to examine the 
relationship between sST2 and LV structure and function in pa-
tients with MetS. An increased sST2 concentration in patients 
with MetS was associated with a greater likelihood of exhibiting 
LVH. sST2 was a more powerful predictor for LVH than SBP. Our 
results suggest that inflammation could be one of the principal 
triggering mechanisms for LV remodeling in MetS. According to 
our findings, sST2 might be a useful biomarker in the early as-
sessment of LV remodeling in MetS. Future studies on the prog-
nostic utility of sST2 and therapeutic strategies targeted toward 
the IL family in MetS are necessary.
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